Bank of America initiated coverage on Zoetis ZTS with a Neutral rating and a $35.00 price objective.
Bank of America analyst Robert M. Willoughby commented, "Clear competitive advantages should enable Zoetis to grow EPS at a long term annual rate of 15%, which, along with low capital expenditures, better working capital management, and deleveraging, affords it ample leverage to improve ROIC. … With its shares up 30% (vs. +4% S&P500) since its January 31 IPO, Zoetis clearly has benefited from a veterinary focus that shelters it from reimbursement and regulatory challenges, research and development inefficiencies, and other issues overhanging the human health sector."
Zoetis closed at $33.82 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in